Trial reportExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association2006
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Trial report in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01511172. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.Diabetes, obesity & metabolism · 2026Pooled it
- Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.International wound journal · 2024Pooled it
- Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2019 · on this mapPooled it
- Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.Open medicine : a peer-reviewed, independent, open-access journal · 2011Pooled it
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.British journal of clinical pharmacology · 2010Trial
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.British journal of clinical pharmacology · 2009 · on this mapTrial
- Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.Diabetes care · 2009 · on this mapTrial
- Molecular basis for cross-activation of NPFF2R by a short PrRP-related peptide.Acta pharmacologica Sinica · 2026Article
- Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.ACS pharmacology & translational science · 2019Article
- Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.Scientific reports · 2019Article
- Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment.Scientific reports · 2018Article
- Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.Endocrine · 2015Article
- Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.Clinical medicine insights. Endocrinology and diabetes · 2015Article
- Establishment of a pancreatic β cell proliferation model in vitro and a platform for diabetes drug screening.Cytotechnology · 2014Article
- GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Drug design, development and therapy · 2014Review
- Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?Diabetologia · 2013Article
- Metformin and its clinical use: new insights for an old drug in clinical practice.Archives of medical science : AMS · 2012Article
- Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Liraglutide in the management of type 2 diabetes.Drug design, development and therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEffects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes.
methods144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label). The dose of liraglutide was increased weekly from 0.5 to 2 mg OD.
resultsLiraglutide added to metformin monotherapy was associated with a significant reduction in fasting serum glucose (FSG) (-3.9 mM -4.9; -2.9) (primary objective), and HbA1c levels (-0.8% -1.2; -0.4). Furthermore, liraglutide in combination with metformin vs. metformin plus glimepiride significantly reduced FSG (-1.2 mM -2.2; -0.2). In addition, body weight was significantly lower in the metformin plus liraglutide vs. the metformin plus glimepiride group (-2.9 kg -3.6; -2.1). There were no biochemically confirmed episodes of hypoglycaemia with liraglutide treatment. Nausea was the most frequently reported adverse event following liraglutide therapy, it was transient in nature, and led to withdrawal of only 4% of the subjects.
conclusionsUsing a weekly dose-titration liraglutide is well tolerated up to 2 mg daily. While liraglutide caused transient gastrointestinal side effects, this rarely interfered with continuing treatment. An improvement in FSG over that in control groups was seen for liraglutide as an add-on to metformin. In the latter case, body weight was reduced in comparison to metformin plus glimepiride. Liraglutide is a promising drug for the treatment of type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.